Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus as first-line treatment in advanced gastrointestinal and pancreatic neuroendocrine tumors
2011-006160-48Phase 2Terminated
- Sponsor
- HeCOG
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in gastrointestinal neuroendocrine neoplasm (GI-NEN) and islet cell tumor, sponsored by HeCOG. Primary endpoints: Progression-free survival rate at 15 months and Progression-free survival. Started Apr 2012; status: terminated.
02
Drugs
everolimus
03
Conditions
gastrointestinal neuroendocrine neoplasm (GI-NEN)islet cell tumor
Beyond the preview
Go deeper on 2011-006160-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006160-48.